Skip to main content

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or P13K-Delta Inhibitor Therapy

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

September 1, 2016

End Date

September 1, 2022
 

Administered By

Duke Cancer Institute

Awarded By

TG Therapeutics, Inc

Start Date

September 1, 2016

End Date

September 1, 2022